Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC.
- Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC.
- At present, seven other regulatory agencies have joined Project Orbis, including the TGA, Singapore Health Sciences Authority (HSA), Health Canada (HC), MHRA, etc.
- Toripalimab for the treatment of NPC meets these application requirements and is the first domestic oncology drug to be included in Project Orbis.
- Junshi Biosciences will explore the possibility of fast marketing in these countries and regions where the pathway is applicable.